In human cancer cells, combination therapy with OBP-301 and Ad-p53 yields more profound antitumor efficacy than does monotherapy with OBP-301 [100], suggesting that the activation of the p53 signaling pathway enhances the antitumor efficacy of OBP-301. Here, TP53 is linked to cancer.